Latest News and Press Releases

Oslo, 24 May 2023. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and shall...

Oslo (Norway), 12 May 2023 – PCI Biotech (OSE: PCIB), today announces its interim Q1 2023 results. Please find enclosed the report and presentation. Highlights reviewfimaNAc – bioprocessingThe...

Oslo, Norway, 9 May 2023 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's Q1 2023 interim report on Friday 12 May 2023, 08:30am – 09:30am CEST (local time). The...

Oslo, Norway 4 May 2023 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 25 May 2023 at 10:00am (CEST). The...

Oslo, Norway, April 28, 2023The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2022. Please find the report attached, as well as the report according to the European...

Oslo (Norway), 17 February 2023 – PCI Biotech (OSE: PCIB), today announces its interim Q4 2022 results. Please find enclosed the report and presentation. Highlights fimaNAc – dermatology and...

Oslo, Norway, 13 February 2023 - PCI Biotech (OSE: PCIB) invites to an online presentation of the company's Q4 2022 interim report on Friday 17 February 2023, 08:30am – 09:30am CET (local time). The...

Myrlid AS har i dag, 20. januar 2023, solgt 450 000 aksjer i PCI Biotech Holding ASA ("Selskapet"). Som følge av salget innehar Myrlid AS etter dette totalt 1 450 000 aksjer og stemmer i Selskapet...

Oslo, 25 November 2022 - PCI Biotech (OSE: PCIB), today announce that the Board of Directors has granted share options to key employees.         In accordance with the authorisation granted by the...

Oslo (Norway), 23 November 2022 – PCI Biotech (OSE: PCIB), today announces its interim Q3 2022 results. Please find enclosed the report and presentation. Highlights Corporate*Efforts to finance a Ph...